Lysogene – Ongoing Phase 2/3 clinical trial for Sanfilippo syndrome Type A (MPS IIIA)
Ongoing Phase 2/3 clinical trial for Sanfilippo syndrome Type A (MPS IIIA) In October 2018, Lysogene, a company focused on pioneering gene therapies for CNS disorders, partnered with Sarepta Therapeutics to move forward on the AAVance MPS IIIA clinical trial. The Phase 2/3 gene therapy trial started in December 2018. AAVance is currently recruiting patients for [...]